{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:24:20Z","timestamp":1780503860168,"version":"3.54.1"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The renin-angiotensin system (RAS) has been reported to have a role in carcinogenesis, and\ntherefore it may be of value as a potential therapeutic target in inhibiting tumor growth. It has been\nshown that inhibition of RAS via angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin\nII type-1 receptor (ARBs) inhibitors may have a protective effect against several malignancies. Here,\nwe provide an overview of the potential value of the RAS pathway and targeting via ACE\/ARB inhibitors\nin pancreatic cancer. Whilst the potential role of RAS as a target for the treatment of pancreatic\ncancer has been reported, the use of candesartan with gemcitabine failed to improve outcomes in pancreatic\ncancer. Another study of 1-3 years using ARB was found to reduce the risk of pancreatic cancer.\nIn line with these trials, others have demonstrated that the ARBs in combination with gemcitabine\nmight improve clinical outcomes in patients with advanced pancreatic cancer. Prospective trials are\nwarranted to investigate this hypothesis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009622666220517104411","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:57:34Z","timestamp":1652939854000},"page":"785-795","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor\nBlockers as Potential Therapeutic Options for Pancreatic Cancer"],"prefix":"10.2174","volume":"22","author":[{"given":"Fereshteh","family":"Asgharzadeh","sequence":"first","affiliation":[{"name":"Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiarash Roustai","family":"Geraylow","sequence":"first","affiliation":[{"name":"Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Khazaei","sequence":"first","affiliation":[{"name":"Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Metabolic Syndrome Research\nCenter, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Avan","sequence":"first","affiliation":[{"name":"Metabolic Syndrome Research\nCenter, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Medical Genetics Research Center, Faculty of\nMedicine, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Basic Sciences Research Institute, Mashhad University\nof Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Nassiri","sequence":"additional","affiliation":[{"name":"Recombinant Proteins Research Group, The Research\nInstitute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahdi","family":"Hassanian","sequence":"additional","affiliation":[{"name":"Metabolic Syndrome Research\nCenter, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Department of Clinical Biochemistry,\nFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon A","family":"Ferns","sequence":"additional","affiliation":[{"name":"Brighton & Sussex Medical School,\nDivision of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1042\/BST20170521","volume":"47","author":"Lanfredini S.","year":"2019","unstructured":"Lanfredini S.; Thapa A.; O\u2019Neill E.; RAS in pancreatic cancer. Biochem Soc Trans 2019,47(4),961-972","journal-title":"Biochem Soc Trans"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"McGuigan A.","year":"2018","unstructured":"McGuigan A.; Kelly P.; Turkington R.C.; Jones C.; Coleman H.G.; McCain R.S.; Pancreatic cancer: A review of clinical diagnosis, epi-demiology, treatment and outcomes. World J Gastroenterol 2018,24(43),4846-4861","journal-title":"World J Gastroenterol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"Mizrahi J.D.","year":"2020","unstructured":"Mizrahi J.D.; Surana R.; Valle J.W.; Shroff R.T.; Pancreatic cancer. Lancet 2020,395(10242),2008-2020","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.31128\/AJGP-06-19-4957","volume":"48","author":"Loveday B.P.T.","year":"2019","unstructured":"Loveday B.P.T.; Lipton L.; Thomson B.N.J.; Pancreatic cancer: An update on diagnosis and management. Aust J Gen Pract 2019,48(12),826-831","journal-title":"Aust J Gen Pract"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"Neoptolemos J.P.","year":"2018","unstructured":"Neoptolemos J.P.; Kleeff J.; Michl P.; Costello E.; Greenhalf W.; Palmer D.H.; Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat Rev Gastroenterol Hepatol 2018,15(6),333-348","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"153010","DOI":"10.1016\/j.prp.2020.153010","volume":"216","author":"Hashemzehi M.","year":"2020","unstructured":"Hashemzehi M.; Beheshti F.; Hassanian S.M.; Ferns G.A.; Khazaei M.; Avan A.; Therapeutic potential of renin angiotensin system inhibitors in cancer cells metastasis. Pathol Res Pract 2020,216(7),153010-153010","journal-title":"Pathol Res Pract"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"Pinter M.","year":"2017","unstructured":"Pinter M.; Jain R.K.; Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 2017,9(410),9","journal-title":"Sci Transl Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"George A.J.","year":"2010","unstructured":"George A.J.; Thomas W.G.; Hannan R.D.; The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer 2010,10(11),745-759","journal-title":"Nat Rev Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.23215","volume":"112","author":"van der Knaap R.","year":"2008","unstructured":"van der Knaap R.; Siemes C.; Coebergh J.W.; van Duijn C.M.; Hofman A.; Stricker B.H.; Renin-angiotensin system inhibitors, angio-tensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: The Rotterdam Study. Cancer 2008,112(4),748-757","journal-title":"Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12094-020-02488-3","volume":"23","author":"Afsar B.","year":"2021","unstructured":"Afsar B.; Afsar R.E.; Ertuglu L.A.; Kuwabara M.; Ortiz A.; Covic A.; Kanbay M.; Renin-angiotensin system and cancer: Epidemiology, cell signaling, genetics and epigenetics. Clin Transl Oncol 2021,23,682-696","journal-title":"Clin Transl Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","volume":"16","author":"Deshayes F.","year":"2005","unstructured":"Deshayes F.; Nahmias C.; Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005,16(7),293-299","journal-title":"Trends Endocrinol Metab"},{"key":"ref=12","first-page":"360","volume":"29","author":"Liao Y.D.","year":"2007","unstructured":"Liao Y.D.; Xu H.; Han Q.; Lei J.; Zhang Y.Y.; Wang Z.H.; Expression of angiotensin II type 1 receptor in cervical squamous cell carci-noma and its clinical significance. Zhonghua Zhong Liu Za Zhi 2007,29(5),360-364","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref=13","first-page":"1418","volume":"18","author":"Peng M.Y.","year":"2010","unstructured":"Peng M.Y.; Wang L.L.; Liang T.; Zhao X.L.; Wang G.P.; Chen F.P.; Expression of angiotensin-II type 1 receptor at1 mRNA in myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010,18(6),1418-1421","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1470320313496858","volume":"16","author":"Wegman-Ostrosky T.","year":"2015","unstructured":"Wegman-Ostrosky T.; Soto-Reyes E.; Vidal-Mill\u00e1n S.; S\u00e1nchez-Corona J.; The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst 2015,16(2),227-233","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"Sipahi I.","year":"2010","unstructured":"Sipahi I.; Debanne S.M.; Rowland D.Y.; Simon D.I.; Fang J.C.; Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol 2010,11(7),627-636","journal-title":"Lancet Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","volume":"29","author":"Collaboration A.T.","year":"2011","unstructured":"Collaboration A.T.; Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 indi-viduals. J Hypertens 2011,29(4),623-635","journal-title":"J Hypertens"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","volume":"108","author":"Sipahi I.","year":"2011","unstructured":"Sipahi I.; Chou J.; Mishra P.; Debanne S.M.; Simon D.I.; Fang J.C.; Meta-analysis of randomized controlled trials on effect of angioten-sin-converting enzyme inhibitors on cancer risk. Am J Cardiol 2011,108(2),294-301","journal-title":"Am J Cardiol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","volume":"123","author":"Pasternak B.","year":"2011","unstructured":"Pasternak B.; Svanstr\u00f6m H.; Callr\u00e9us T.; Melbye M.; Hviid A.; Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011,123,1729-1736","journal-title":"Circulation"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.04.019","volume":"64","author":"Datzmann T.","year":"2019","unstructured":"Datzmann T.; Fuchs S.; Andree D.; Hohenstein B.; Schmitt J.; Schindler C.; Systematic review and meta-analysis of randomised con-trolled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur J Intern Med 2019,64,1-9","journal-title":"Eur J Intern Med"},{"key":"ref=20","first-page":"35","volume":"34","author":"Dong-Mei L.","year":"2021","unstructured":"Dong-Mei L.; Wei Z.; Guang-Jun H.; Lu J.; Jian-Lun H.; Jian Z.; Drugs affecting renin-angiotensin-aldosterone system and the cancer risk: A meta-analysis of nested case-control studies. Pak J Pharm Sci 2021,34(1),35-39","journal-title":"Pak J Pharm Sci"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","volume":"26","author":"Song T.","year":"2017","unstructured":"Song T.; Choi C.H.; Kim M.K.; Kim M.L.; Yun B.S.; Seong S.J.; The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. Eur J Cancer Prev 2017,26,78-85","journal-title":"Eur J Cancer Prev"},{"key":"ref=22","first-page":"1375","volume":"21","author":"Li X.Y.","year":"2017","unstructured":"Li X.Y.; Sun J.F.; Hu S.Q.; The renin-angiotensin system blockers as adjunctive therapy for cancer: A meta-analysis of survival out-come. Eur Rev Med Pharmacol Sci 2017,21(6),1375-1383","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e6394","DOI":"10.1097\/MD.0000000000006394","volume":"96","author":"Sun H.","year":"2017","unstructured":"Sun H.; Li T.; Zhuang R.; Cai W.; Zheng Y.; Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies. Medicine (Baltimore) 2017,96(13),e6394-e6394","journal-title":"Medicine (Baltimore)"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"117181","DOI":"10.1016\/j.lfs.2019.117181","volume":"242","author":"Asgharzadeh F.","year":"2020","unstructured":"Asgharzadeh F.; Hashemzehi M.; Moradi-Marjaneh R.; Hassanian S.M.; Ferns G.A.; Khazaei M.; Avan A.; Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis. Life Sci 2020,242,117181-117181","journal-title":"Life Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e19075","DOI":"10.1097\/MD.0000000000019075","volume":"99","author":"Zhou Q.","year":"2020","unstructured":"Zhou Q.; Chen D-S.; Xin L.; Zhou L-Q.; Zhang H-T.; Liu L.; Yuan Y-W.; Li S-H.; The renin-angiotensin system blockers and survival in digestive system malignancies: A systematic review and meta-analysis. Medicine (Baltimore) 2020,99(7),e19075-e19075","journal-title":"Medicine (Baltimore)"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1177\/1470320319895646","volume":"21","author":"Chen X.","year":"2020","unstructured":"Chen X.; Yi C.H.; Ya K.G.; Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta anal-ysis. J Renin Angiotensin Aldosterone Syst 2020,21(3)","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.2174\/1381612826666200713165018","volume":"26","author":"Asgharzadeh F.","year":"2020","unstructured":"Asgharzadeh F.; Jafarzadeh-Esfehani R.; Hassanian S.M.; Ferns G.A.; Avan A.; Khazaei M.; Renin-angiotensin system inhibitors and development of hepatocellular carcinoma: A systematic review and meta-analysis. Curr Pharm Des 2020,26(39),5079-5085","journal-title":"Curr Pharm Des"},{"key":"ref=28","first-page":"12656","volume":"8","author":"Zhang J.","year":"2015","unstructured":"Zhang J.; Liu J.; Chen J.; Li X.; Wu Y.; Chen H.; Wu W.; Zhang K.; Gu L.; Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: A systematic review and meta-analysis. Int J Clin Exp Med 2015,8(8),12656-12660","journal-title":"Int J Clin Exp Med"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.609901","volume":"12","author":"Xie Y.","year":"2021","unstructured":"Xie Y.; Wang M.; Xu P.; Deng Y.; Zheng Y.; Yang S.; Wu Y.; Zhai Z.; Zhang D.; Li N.; Wang N.; Cheng J.; Dai Z.; Association between antihypertensive medication use and breast cancer: A systematic review and meta-analysis. Front Pharmacol 2021,12","journal-title":"Front Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12894-018-0318-7","volume":"18","author":"Cao L.","year":"2018","unstructured":"Cao L.; Zhang S.; Jia C.M.; He W.; Wu L.T.; Li Y.Q.; Wang W.; Li Z.; Ma J.; Antihypertensive drugs use and the risk of prostate cancer: A meta-analysis of 21 observational studies. BMC Urol 2018,18(1),17","journal-title":"BMC Urol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1113\/jphysiol.2006.126193","volume":"580","author":"Leung P.S.","year":"2007","unstructured":"Leung P.S.; The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007,580(Pt 1),31-37","journal-title":"J Physiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1365-2036.2011.04810.x","volume":"34","author":"Skipworth J.R.","year":"2011","unstructured":"Skipworth J.R.; Szabadkai G.; Olde Damink S.W.; Leung P.S.; Humphries S.E.; Montgomery H.E.; Pancreatic renin-angiotensin sys-tems in health and disease. Aliment Pharmacol Ther 2011,34(8),840-852","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1677\/joe.0.1600013","volume":"160","author":"Leung P.S.","year":"1999","unstructured":"Leung P.S.; Chan W.P.; Wong T.P.; Sernia C.; Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 1999,160(1),13-19","journal-title":"J Endocrinol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/MPA.0000000000000125","volume":"43","author":"Kim S.","year":"2014","unstructured":"Kim S.; Toyokawa H.; Yamao J.; Satoi S.; Yanagimoto H.; Yamamoto T.; Hirooka S.; Yamaki S.; Inoue K.; Matsui Y.; Kwon A.H.; Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Pancreas 2014,43(6),886-890","journal-title":"Pancreas"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jamcollsurg.2007.01.067","volume":"204","author":"Arafat H.A.","year":"2007","unstructured":"Arafat H.A.; Gong Q.; Chipitsyna G.; Rizvi A.; Saa C.T.; Yeo C.J.; Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007,204(5),996-1005","journal-title":"J Am Coll Surg"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e31384","DOI":"10.1371\/journal.pone.0031384","volume":"7","author":"Arnold S.A.","year":"2012","unstructured":"Arnold S.A.; Rivera L.B.; Carbon J.G.; Toombs J.E.; Chang C-L.; Bradshaw A.D.; Brekken R.A.; Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF\u03b2 activation. PLoS One 2012,7(2),e31384-e31384","journal-title":"PLoS One"},{"key":"ref=37","first-page":"355","volume":"22","author":"Noguchi R.","year":"2009","unstructured":"Noguchi R.; Yoshiji H.; Ikenaka Y.; Namisaki T.; Kitade M.; Kaji K.; Yoshii J.; Yanase K.; Yamazaki M.; Tsujimoto T.; Kawaratani H.; Fukui H.; Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep 2009,22(2),355-360","journal-title":"Oncol Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/MPA.0b013e3181c314cd","volume":"39","author":"Gong Q.","year":"2010","unstructured":"Gong Q.; Davis M.; Chipitsyna G.; Yeo C.J.; Arafat H.A.; Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 2010,39(5),581-594","journal-title":"Pancreas"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3109\/00365521.2013.777776","volume":"48","author":"Masamune A.","year":"2013","unstructured":"Masamune A.; Hamada S.; Kikuta K.; Takikawa T.; Miura S.; Nakano E.; Shimosegawa T.; The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol 2013,48(5),602-609","journal-title":"Scand J Gastroenterol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tranon.2016.07.004","volume":"9","author":"Kumar V.","year":"2016","unstructured":"Kumar V.; Boucher Y.; Liu H.; Ferreira D.; Hooker J.; Catana C.; Hoover A.J.; Ritter T.; Jain R.K.; Guimaraes A.R.; Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma. Transl Oncol 2016,9(5),431-437","journal-title":"Transl Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"119118","DOI":"10.1016\/j.lfs.2021.119118","volume":"270","author":"Khoshghamat N.","year":"2021","unstructured":"Khoshghamat N.; Jafari N.; Toloue-Pouya V.; Azami S.; Mirnourbakhsh S.H.; Khazaei M.; Ferns G.A.; Rajabian M.; Avan A.; The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Life Sci 2021,270,119118-119118","journal-title":"Life Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"Chauhan V.P.","year":"2013","unstructured":"Chauhan V.P.; Martin J.D.; Liu H.; Lacorre D.A.; Jain S.R.; Kozin S.V.; Stylianopoulos T.; Mousa A.S.; Han X.; Adstamongkonkul P.; Popovi\u0107 Z.; Huang P.; Bawendi M.G.; Boucher Y.; Jain R.K.; Angiotensin inhibition enhances drug delivery and potentiates chemo-therapy by decompressing tumour blood vessels. Nat Commun 2013,4,2516-2516","journal-title":"Nat Commun"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/gut.2009.188961","volume":"59","author":"Fendrich V.","year":"2010","unstructured":"Fendrich V.; Chen N-M.; Neef M.; Waldmann J.; Buchholz M.; Feldmann G.; Slater E.P.; Maitra A.; Bartsch D.K.; The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genet-ically engineered mouse model of pancreatic cancer. Gut 2010,59(5),630-637","journal-title":"Gut"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3181\/00379727-210-43942","volume":"210","author":"Reddy M.K.","year":"1995","unstructured":"Reddy M.K.; Baskaran K.; Molteni A.; Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995,210(3),221-226","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.1073\/pnas.0900351106","volume":"106","author":"Rhodes D.R.","year":"2009","unstructured":"Rhodes D.R.; Ateeq B.; Cao Q.; Tomlins S.A.; Mehra R.; Laxman B.; Kalyana-Sundaram S.; Lonigro R.J.; Helgeson B.E.; Bhojani M.S.; Rehemtulla A.; Kleer C.G.; Hayes D.F.; Lucas P.C.; Varambally S.; Chinnaiyan A.M.; AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA 2009,106(25),10284-10289","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.bjc.6690048","volume":"79","author":"Foekens J.A.","year":"1999","unstructured":"Foekens J.A.; Look M.P.; Bolt-de Vries J.; Meijer-van Gelder M.E.; van Putten W.L.; Klijn J.G.; Cathepsin-D in primary breast cancer: Prognostic evaluation involving 2810 patients. Br J Cancer 1999,79(2),300-307","journal-title":"Br J Cancer"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(82)92782-9","volume":"2","author":"Jones V.A.","year":"1982","unstructured":"Jones V.A.; McLaughlan P.; Shorthouse M.; Workman E.; Hunter J.O.; Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982,2(8308),1115-1117","journal-title":"Lancet"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM199002013220504","volume":"322","author":"Tandon A.K.","year":"1990","unstructured":"Tandon A.K.; Clark G.M.; Chamness G.C.; Chirgwin J.M.; McGuire W.L.; Cathepsin D and prognosis in breast cancer. N Engl J Med 1990,322(5),297-302","journal-title":"N Engl J Med"},{"key":"ref=49","first-page":"6008","volume":"49","author":"Thorpe S.M.","year":"1989","unstructured":"Thorpe S.M.; Rochefort H.; Garcia M.; Freiss G.; Christensen I.J.; Khalaf S.; Paolucci F.; Pau B.; Rasmussen B.B.; Rose C.; Associa-tion between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989,49(21),6008-6014","journal-title":"Cancer Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000227464","volume":"52","author":"Tumminello F.M.","year":"1995","unstructured":"Tumminello F.M.; Gebbia N.; Pizzolanti G.; Russo A.; Bazan V.; Leto G.; Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: A preliminary report. Oncology 1995,52(3),237-242","journal-title":"Oncology"},{"key":"ref=51","first-page":"1809","volume":"5","author":"Garcia M.","year":"1990","unstructured":"Garcia M.; Derocq D.; Pujol P.; Rochefort H.; Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990,5(12),1809-1814","journal-title":"Oncogene"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF00049522","volume":"9","author":"Rochefort H.","year":"1990","unstructured":"Rochefort H.; Capony F.; Garcia M.; Cathepsin D.; A protease involved in breast cancer metastasis. Cancer Metastasis Rev 1990,9(4),321-331","journal-title":"Cancer Metastasis Rev"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6914976","volume":"2017","author":"Goldstein B.","year":"2017","unstructured":"Goldstein B.; Trivedi M.; Speth R.C.; Alterations in gene expression of components of the renin-angiotensin system and its related en-zymes in lung cancer. Lung Cancer Int 2017,2017","journal-title":"Lung Cancer Int"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/labinvest.3700504","volume":"87","author":"Imai N.","year":"2007","unstructured":"Imai N.; Hashimoto T.; Kihara M.; Yoshida S.; Kawana I.; Yazawa T.; Kitamura H.; Umemura S.; Roles for host and tumor angioten-sin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 2007,87(2),189-198","journal-title":"Lab Invest"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","volume":"11","author":"Suganuma T.","year":"2005","unstructured":"Suganuma T.; Ino K.; Shibata K.; Kajiyama H.; Nagasaka T.; Mizutani S.; Kikkawa F.; Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peri-toneal dissemination. Clin Cancer Res 2005,11(7),2686-2694","journal-title":"Clin Cancer Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2407-10-67","volume":"10","author":"Doi C.","year":"2010","unstructured":"Doi C.; Egashira N.; Kawabata A.; Maurya D.K.; Ohta N.; Uppalapati D.; Ayuzawa R.; Pickel L.; Isayama Y.; Troyer D.; Takekoshi S.; Tamura M.; Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 2010,10,67","journal-title":"BMC Cancer"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/pros.20407","volume":"66","author":"Uemura H.","year":"2006","unstructured":"Uemura H.; Hasumi H.; Ishiguro H.; Teranishi J.; Miyoshi Y.; Kubota Y.; Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006,66(8),822-830","journal-title":"Prostate"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ajcp\/104.1.36","volume":"104","author":"Ross J.S.","year":"1995","unstructured":"Ross J.S.; Nazeer T.; Figge H.L.; Fisher H.A.; Rifkin M.D.; Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status. Am J Clin Pathol 1995,104(1),36-41","journal-title":"Am J Clin Pathol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/sj.bjc.6605866","volume":"103","author":"Dolley-Hitze T.","year":"2010","unstructured":"Dolley-Hitze T.; Jouan F.; Martin B.; Mottier S.; Edeline J.; Moranne O.; Le Pogamp P.; Belaud-Rotureau M-A.; Patard J-J.; Rioux-Leclercq N.; Vigneau C.; Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010,103(11),1698-1705","journal-title":"Br J Cancer"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-16-0082","volume":"6","author":"Delforce S.J.","year":"2017","unstructured":"Delforce S.J.; Lumbers E.R.; Corbisier de Meaultsart C.; Wang Y.; Proietto A.; Otton G.; Scurry J.; Verrills N.M.; Scott R.J.; Pringle K.G.; Expression of Renin-Angiotensin System (RAS) components in endometrial cancer. Endocr Connect 2017,6(1),9-19","journal-title":"Endocr Connect"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.4161\/cbt.6.8.4412","volume":"6","author":"Carl-McGrath S.","year":"2007","unstructured":"Carl-McGrath S.; Ebert M.P.; Lendeckel U.; R\u00f6cken C.; Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther 2007,6(8),1218-1226","journal-title":"Cancer Biol Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1158\/1078-0432.CCR-04-1922","volume":"11","author":"R\u00f6cken C.","year":"2005","unstructured":"R\u00f6cken C.; Lendeckel U.; Dierkes J.; Westphal S.; Carl-McGrath S.; Peters B.; Kr\u00fcger S.; Malfertheiner P.; Roessner A.; Ebert M.P.; The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion\/deletion poly-morphism. Clin Cancer Res 2005,11(7),2526-2530","journal-title":"Clin Cancer Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1002\/pmic.200800861","volume":"9","author":"Kanshin E.","year":"2009","unstructured":"Kanshin E.; Wang S.; Ashmarina L.; Fedjaev M.; Nifant\u2019ev I.; Mitchell G.A.; Pshezhetsky A.V.; The stoichiometry of protein phos-phorylation in adipocyte lipid droplets: Analysis by N-terminal isotope tagging and enzymatic dephosphorylation. Proteomics 2009,9(22),5067-5077","journal-title":"Proteomics"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1172\/JCI16645","volume":"112","author":"Egami K.","year":"2003","unstructured":"Egami K.; Murohara T.; Shimada T.; Sasaki K.; Shintani S.; Sugaya T.; Ishii M.; Akagi T.; Ikeda H.; Matsuishi T.; Imaizumi T.; Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003,112(1),67-75","journal-title":"J Clin Invest"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/1523-1747.ep12665371","volume":"104","author":"Podhajcer O.L.","year":"1995","unstructured":"Podhajcer O.L.; Bover L.; Bravo A.I.; Ledda M.F.; Kairiyama C.; Calb I.; Guerra L.; Capony F.; Mordoh J.; Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 1995,104(3),340-344","journal-title":"J Invest Dermatol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/carcin\/bgh324","volume":"26","author":"Fujita M.","year":"2005","unstructured":"Fujita M.; Hayashi I.; Yamashina S.; Fukamizu A.; Itoman M.; Majima M.; Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005,26(2),271-279","journal-title":"Carcinogenesis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/ijc.25234","volume":"127","author":"Clere N.","year":"2010","unstructured":"Clere N.; Corre I.; Faure S.; Guihot A.L.; Vessi\u00e8res E.; Chalopin M.; Morel A.; Coqueret O.; Hein L.; Delneste Y.; Paris F.; Henrion D.; Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogene-sis. Int J Cancer 2010,127(10),2279-2291","journal-title":"Int J Cancer"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1158\/1078-0432.CCR-05-2213","volume":"12","author":"Kosugi M.","year":"2006","unstructured":"Kosugi M.; Miyajima A.; Kikuchi E.; Horiguchi Y.; Murai M.; Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006,12(9),2888-2893","journal-title":"Clin Cancer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.canlet.2012.10.006","volume":"328","author":"Chen X.","year":"2013","unstructured":"Chen X.; Meng Q.; Zhao Y.; Liu M.; Li D.; Yang Y.; Sun L.; Sui G.; Cai L.; Dong X.; Angiotensin II type 1 receptor antagonists in-hibit cell proliferation and angiogenesis in breast cancer. Cancer Lett 2013,328(2),318-324","journal-title":"Cancer Lett"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbamcr.2016.03.010","volume":"1863","author":"Oh E.","year":"2016","unstructured":"Oh E.; Kim J.Y.; Cho Y.; An H.; Lee N.; Jo H.; Ban C.; Seo J.H.; Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. Biochim Biophys Acta 2016,1863(6 Pt A),1071-1081","journal-title":"Biochim Biophys Acta"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"R577","DOI":"10.1530\/ERC-16-0067","volume":"23","year":"2016","unstructured":"Peiling Yang, S.; Ngeow, J.Familial non-medullary thyroid cancer: Unraveling the genetic maze. Endocr Relat Cancer 2016,23(12),R577-R595","journal-title":"Endocr Relat Cancer"},{"key":"ref=72","first-page":"927","volume":"19","author":"Hashemzehi M.","year":"2020","unstructured":"Hashemzehi M.; Naghibzadeh N.; Asgharzadeh F.; Mostafapour A.; Hassanian S.M.; Ferns G.A.; Cho W.C.; Avan A.; Khazaei M.; The therapeutic potential of losartan in lung metastasis of colorectal cancer. EXCLI J 2020,19,927-935","journal-title":"EXCLI J"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/j.1440-1746.2006.04152.x","volume":"21","author":"Seow C.H.","year":"2006","unstructured":"Seow C.H.; Leber J.M.; Ee H.C.; Yusoff I.F.; Survey of consent practices for inpatient colonoscopy and endoscopic retrograde cholangi-opancreatography at a tertiary referral center. J Gastroenterol Hepatol 2006,21(8),1340-1345","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09513590.2014.958991","volume":"31","author":"Matysiak Z.E.","year":"2015","unstructured":"Matysiak Z.E.; Och\u0119dalski T.; Piastowska-Ciesielska A.W.; The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer. Gynecol Endocrinol 2015,31(1),1-6","journal-title":"Gynecol Endocrinol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/1470320314535275","volume":"16","author":"Chen Y-H.","year":"2015","unstructured":"Chen Y-H.; Huang C-H.; Lu H-I.; Chen C-H.; Huang W-T.; Hsieh M-J.; Rau K-M.; Chang A.Y.; Lin W-C.; Li S-H.; Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma. J Renin Angiotensin Aldosterone Syst 2015,16(4),1185-1192","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/sj.bjc.6602483","volume":"92","author":"Arrieta O.","year":"2005","unstructured":"Arrieta O.; Guevara P.; Escobar E.; Garc\u00eda-Navarrete R.; Pineda B.; Sotelo J.; Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005,92(7),1247-1252","journal-title":"Br J Cancer"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1470-2045(10)70142-X","volume":"11","author":"Nissen S.E.","year":"2010","unstructured":"Nissen S.E.; Angiotensin-receptor blockers and cancer: Urgent regulatory review needed. Lancet Oncol 2010,11(7),605-606","journal-title":"Lancet Oncol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3892\/ijo_00000287","volume":"34","author":"Kinoshita J.","year":"2009","unstructured":"Kinoshita J.; Fushida S.; Harada S.; Yagi Y.; Fujita H.; Kinami S.; Ninomiya I.; Fujimura T.; Kayahara M.; Yashiro M.; Hirakawa K.; Ohta T.; Local angiotensin II-generation in human gastric cancer: Correlation with tumor progression through the activation of ERK1\/2, NF-kappaB and survivin. Int J Oncol 2009,34(6),1573-1582","journal-title":"Int J Oncol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1038\/s41366-018-0204-0","volume":"43","author":"Roman Y.M.","year":"2019","unstructured":"Roman Y.M.; Dominguez M.C.; Easow T.M.; Pasupuleti V.; White C.M.; Hernandez A.V.; Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: A systematic review and meta-analysis of randomized controlled trials. Int J Obes 2019,43(10),2017-2027","journal-title":"Int J Obes"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/s41388-018-0563-y","volume":"38","author":"Renziehausen A.","year":"2019","unstructured":"Renziehausen A.; Wang H.; Rao B.; Weir L.; Nigro C.L.; Lattanzio L.; Merlano M.; Vega-Rioja A.; Del Carmen Fernandez-Carranco M.; Hajji N.; Matin R.; Harwood C.; Li S.; Sim V.R.; O\u2019Neill K.; Evans A.; Thompson A.; Szlosarek P.; Fleming C.; Stebbing J.; Proby C.; Tzakos A.G.; Syed N.; Crook T.; The Renin Angiotensin System (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. Oncogene 2019,38(13),2320-2336","journal-title":"Oncogene"},{"key":"ref=81","first-page":"4789","volume":"35","author":"Tawinwung S.","year":"2015","unstructured":"Tawinwung S.; Ninsontia C.; Chanvorachote P.; Angiotensin II increases cancer stem cell-like phenotype in lung cancer cells. Anticancer Res 2015,35(9),4789-4797","journal-title":"Anticancer Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00404-015-3661-x","volume":"292","author":"Beyazit F.","year":"2015","unstructured":"Beyazit F.; Ayhan S.; Celik H.T.; Gungor T.; Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet 2015,292(2),415-420","journal-title":"Arch Gynecol Obstet"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037135","volume":"7","author":"Peterson B.K.","year":"2012","unstructured":"Peterson B.K.; Weber J.N.; Kay E.H.; Fisher H.S.; Hoekstra H.E.; Double digest RADseq: An inexpensive method for de novo SNP discovery and genotyping in model and non-model species. PLoS One 2012,7(5)","journal-title":"PLoS One"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopha.2018.01.117","volume":"99","author":"Ahmadian E.","year":"2018","unstructured":"Ahmadian E.; Khosroushahi A.Y.; Eftekhari A.; Farajnia S.; Babaei H.; Eghbal M.A.; Novel angiotensin receptor blocker, azilsartan induces oxidative stress and NFkB-mediated apoptosis in hepatocellular carcinoma cell line HepG2. Biomed Pharmacother 2018,99,939-946","journal-title":"Biomed Pharmacother"},{"key":"ref=85","first-page":"1139","volume":"2","author":"Uemura H.","year":"2003","unstructured":"Uemura H.; Ishiguro H.; Nakaigawa N.; Nagashima Y.; Miyoshi Y.; Fujinami K.; Sakaguchi A.; Kubota Y.; Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003,2(11),1139-1147","journal-title":"Mol Cancer Ther"},{"key":"ref=86","first-page":"107","volume":"11","author":"Scott-Emuakpor J.","year":"2017","unstructured":"Scott-Emuakpor J.; Allot E.; Johnson S.A.; Howard L.E.; Macias E.; Freedland S.J.; Gurley S.B.; Angiotensin receptor signaling and prostate tumor growth in mice. J Exp Ther Oncol 2017,11(2),107-115","journal-title":"J Exp Ther Oncol"},{"key":"ref=87","first-page":"295","volume":"20","author":"Funao K.","year":"2008","unstructured":"Funao K.; Matsuyama M.; Kawahito Y.; Sano H.; Chargui J.; Touraine J-L.; Nakatani T.; Yoshimura R.; Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 2008,20(2),295-300","journal-title":"Oncol Rep"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/bjc.1998.145","volume":"77","author":"Hii S.I.","year":"1998","unstructured":"Hii S.I.; Nicol D.L.; Gotley D.C.; Thompson L.C.; Green M.K.; Jonsson J.R.; Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998,77(6),880-883","journal-title":"Br J Cancer"},{"key":"ref=89","first-page":"4176","volume":"62","author":"Miyajima A.","year":"2002","unstructured":"Miyajima A.; Kosaka T.; Asano T.; Asano T.; Seta K.; Kawai T.; Hayakawa M.; Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002,62(15),4176-4179","journal-title":"Cancer Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/humrep\/dem247","volume":"23","author":"Isobe A.","year":"2008","unstructured":"Isobe A.; Takeda T.; Sakata M.; Miyake A.; Yamamoto T.; Minekawa R.; Nishimoto F.; Oskamoto Y.; Walker C.L.; Kimura T.; Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation. Hum Reprod 2008,23(2),440-446","journal-title":"Hum Reprod"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009622666220517104411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204895\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009622666220517104411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T16:29:34Z","timestamp":1666888174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204895\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":90,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009622666220517104411","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}